These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 20878757)

  • 1. Use of biologics in inflammatory bowel disease patients with cirrhosis.
    Dhere T
    Inflamm Bowel Dis; 2011 Feb; 17(2):E15-6. PubMed ID: 20878757
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-TNF agents in inflammatory bowel disease: indications and management].
    Cocq P; Yazdanpannah Y; Mesnard B; Colombel JF
    Gastroenterol Clin Biol; 2004 May; 28(5 Suppl):D61-9. PubMed ID: 15213665
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract]   [Full Text] [Related]  

  • 4. [Biologics in current therapy for inflammatory bowel disease].
    Hisamatsu T; Hibi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun; 32(3):168-79. PubMed ID: 19564713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
    Dwadasi S; Israel A; Rubin DT
    Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):405-419. PubMed ID: 31078244
    [No Abstract]   [Full Text] [Related]  

  • 7. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New inflammatory bowel disease drugs targeting the inflammatory cascade].
    Desreumaux P
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B72-8. PubMed ID: 11449147
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic potential of infliximab in inflammatory bowel disease.
    Hurd LB; Lichtenstein GR
    Gastroenterol Nurs; 1999; 22(5):199-208. PubMed ID: 10776108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID).
    Chua I; Standish R; Lear S; Harbord M; Eren E; Raeiszadeh M; Workman S; Webster D
    Clin Exp Immunol; 2007 Nov; 150(2):306-11. PubMed ID: 17822445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics in inflammatory disease: infliximab associated risk of lymphoma development.
    Bucher C; Degen L; Dirnhofer S; Pless M; Herrmann R; Schraml P; Went P
    Gut; 2005 May; 54(5):732-3. PubMed ID: 15831931
    [No Abstract]   [Full Text] [Related]  

  • 16. [Perspectives in inflammatory bowel diseases treatment].
    Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.
    Verschueren P; Lensen F; Lerut E; Claes K; De Vos R; Van Damme B; Westhovens R
    Ann Rheum Dis; 2003 Apr; 62(4):368-9. PubMed ID: 12634242
    [No Abstract]   [Full Text] [Related]  

  • 18. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary implications in inflammatory bowel disease: not a rare event.
    Romano C; Cardile S
    Expert Opin Drug Saf; 2016 Aug; 15(8):1001-2. PubMed ID: 27187875
    [No Abstract]   [Full Text] [Related]  

  • 20. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.